Építés alatt – nem éles oldal
Belépés
Résztvevőt keres3. fázis

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

A legfontosabb adatok

Ki végzi
Takeda
Hol
Zagreb (Horvátország)A helyszín megnézéseMég 19 másik országban, 126 helyszínen
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
171 fő, tervezett
Kezdés
2025. febr. 27.
Várható befejezés
2028. márc. 16.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Mezagitamab
  • Placebo
A regiszteradat frissítve
2026. november 4.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with chronic primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. Earlier treatments did not work well enough or caused side effects.

Életkor
18 Years and older
Nem
All sexes can join.
A betegség stádiuma
Primary ITP that has lasted at least 12 months. Mean platelet count less than (<)30,000/μL.
Korábbi kezelés
People must have responded before to an ITP therapy (not a TPO-RA), with a platelet count ≥50,000/μL. They must have had too little response or side effects with at least 1 first-line therapy (for example, corticosteroids) and at least 1 second-line therapy (for example, TPO-RA, rituximab, fostamatinib, mycophenolate). Current standard ITP treatment can continue if the dose has been stable for at least 4 weeks.
Biomarker vagy leletérték
Mean platelet count less than (<)30,000/μL. People who can become pregnant need a negative pregnancy test.

A részvétel fő kizáró okai

  • Secondary ITP (caused by another disease) or removal of the spleen.
  • A blood clot within 12 months before signing consent.
  • Active hepatitis B, hepatitis C or HIV infection.
  • Cancer within 5 years, except treated non-melanoma skin cancer or cervical carcinoma in situ.
  • Prior mezagitamab, recent anti-CD20 treatment, recent blood thinners, or certain recent immune-suppressing drugs.

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • The participant has been diagnosed with ITP that has persisted for at least 12 months
  • The participant's diagnosis of ITP is supported by a prior response to an ITP therapy (not including a thrombopoietin receptor agonist [TPO-RA]), defined as having achieved a platelet count ≥50,000/μL
  • The participant has evidence of insufficient response or intolerance to at least 1 currently available first-line therapy for treatment of ITP (for example, corticosteroids), and at least 1 currently available second-line therapy for treatment of ITP (for example, TPO-RA, rituximab, fostamatinib, mycophenolate). Insufficient response to previous treatment is defined as failure to achieve a sustained platelet count of at least 50,000/μL or doubling of baseline platelet count after an appropriate course of prior ITP treatment. Intolerance is defined as a documented side effect causing discontinuation of the therapy
  • The participant has a mean platelet count of less than (<)30,000/μL
  • If the participant is receiving allowed standard-of-care treatment for ITP at screening, and continued use is intended, treatment may continue during the trial if the dose, and frequency have been stable for at least 4 weeks before receiving the first dose of IMP (i.e., Day 1), and are expected to remain stable throughout the trial
  • If the participant is an individual with potential for pregnancy, the participant is not pregnant as confirmed by negative human chorionic gonadotropin during screening, and before the first dose of trial intervention

Ki nem vehet részt

  • The participant has had any thrombotic or embolic event within 12 months before signing the informed consent form (ICF)
  • The participant has received any monoclonal or polyclonal antibody for immunomodulation within 6 months before screening
  • The participant has any prior exposure to mezagitamab or has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Day 1
  • The participant has used anticoagulants (e.g., vitamin K antagonists, direct oral anticoagulants) within 3 weeks prior to the first dose of trial treatment
  • The participant has received a live or live-attenuated vaccine within 4 weeks prior to the first dose of trial treatment or has any live or live-attenuated vaccine planned during the trial
  • The participant has used the following immunosuppressive agents as specified prior to the first dose of trial treatment: alkylating agents (e.g., cyclophosphamide) within 8 weeks, vinca alkaloids (e.g., vincristine) within 4 weeks, sulfones (e.g., dapsone) within 3 weeks, antiproliferative agents: (e.g., mycophenolate mofetil, and azathioprine) within 2 weeks, and calcineurin inhibitors: (e.g., cyclosporine) within 2 weeks
  • The participant has used intravenous immunoglobulin (IVIg), SC immunoglobulin, recombinant human thrombopoietin, anti-D immunoglobulin treatment, or efgartigimod within 4 weeks before signing the ICF or it is expected that any treatment for thrombocytopenia other than the participant's standard-of-care ITP therapy (e.g., rescue therapy, administration of blood products) may be used between screening, and Day 1
  • The participant has active infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (HIV)
  • History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for treated non-melanoma skin cancer or cervical carcinoma in situ
  • In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol
  • The participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in the mezagitamab/placebo formulation; Other protocol defined inclusion/exclusion criteria may apply
  • The participant has received anti-cluster of differentiation (CD) 20 treatment within 12 months before screening, and either of the following applies:; The last dose was received within 6 months before screening; The last dose was received between 6 and 12 months before screening, and the participant has a cluster of differentiation 19 positive (CD19+) count below the lower limit of normal
  • The participant has secondary ITP
  • The participant has had a splenectomy

Helyszínek itt: Horvátország

Még 19 másik országban, 126 helyszínen

  • University Hospital Centre ZagrebZagreb, HorvátországNo longer taking part

A vizsgálatról

Mit akar kideríteni a vizsgálat

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously [SC]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it.

A teljes eredeti leírásKevesebb

The participants will be treated with mezagitamab for up to 6 months.

During the study, participants will visit their study clinic several times.

Participants who complete the TAK-079-3002 study or do not have any response to study treatment by week 16 (according to study criteria) will be given the opportunity to participate in a continuation study to receive open label mezagitamab (if they are eligible and the site is able to open the continuation study).

A vizsgálat 2 csoportja

  • MezagitamabA vizsgált kezelés

    Participants will receive mezagitamab injection, SC, once weekly (QW). They will receive 8 weekly doses, followed by 8 weekly doses off, and then receive 8 more weekly doses.

  • PlaceboPlacebo, összehasonlításként

    Participants will receive mezagitamab-matching placebo injection, SC, QW. They will receive 8 weekly doses, followed by 8 weekly doses off, and then receive 8 more weekly doses.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. november 4.